NiveshDaily October 14, 2014 INDICES Indices Previous (day) Close % chg Sensex Nifty 26,384.07 7,884.25 +0.33% +0.31% (As on 13th October, 2014) FROM RESEARCH DESK Economy Update Consumer Price Index (CPI) inflation declines to 6.5% in September 2014; lowest since January 2012 Results Preview Bajaj Auto, Bajaj Finance & NIIT Tech (15-Oct-14) Result Updates Reliance Industries Ltd. |Q2FY15 Result Update | PAT above expectation, maintain buy with target price of Rs.1,274 Liberty Shoes Ltd.|Q2FY15 Result Update | Disappointing performance on bottomline; downgrade to HOLD with revised target price of Rs 336 Research Update included Q2FY15E Results Preview | Pharma Sector | Aggregate y-y growth in earnings to slow down a bit on high base of past year; however outlook remains promising IndiaNivesh Universe | Valuation Table Result Today Daljeet S. Kohli Head of Research Mobile: +91 77383 93371, 99205 94087 Tel: +91 22 66188826 [email protected] IndiaNivesh Research IndiaNivesh Securities Private Limited 601 & 602, Sukh Sagar, N. S. Patkar Marg, Girgaum Chowpatty, Mumbai 400 007. Tel: (022) 66188800 IndiaNivesh Research is also available on Bloomberg INNS, Thomson First Call, Reuters and Factiva INDNIV. Results Preview Abhishek Jain Research Analyst Mobile: +91 77383 93433 Tel: +91 22 66188832 [email protected] Bajaj Auto Quick Fundamentals (Rs. Mn) Volume(Unit) Revenue Average realization EBIDTA PAT EPS (RS.) EBITDA PAT Q2 FY15e Q1 FY15 Q2 FY14 QoQ % YoY % 1055582 988430 961330 7 10 55524 51334 50615 8 10 52600 51935 52651 1 ‐0 10684 9251 11320 15 ‐6 8252 7400 8372 12 ‐1 28.53 25.58 28.94 12 ‐1 Margin % Margin % Basis Points (BPS) Margin % 19.2 18.0 22.4 122 (312) 14.9 14.4 16.5 45 (168) Source: Capitaline; IndiaNivesh Research The company witnessed 10% YoY and 7% QoQ growth in volume led by strong performance in export market. Domestic sales decreased by 4% YoY which was offset by 29% YoY growth in export sales. Two wheeler volume increased by 5.9% YoY and three wheeler sales increased by 39.6% YoY. Average realization expected to increase by 1% QoQ to Rs. 52600 due to higher 3W and export sales. EBITDA margin to expand 122 bps QoQ to 19.2% lead by favorable mix higher share 3W and export sales. Key things to point out (1) Strategy for revival in domestic motorcycle sales (2) outlook for export sales growth 3) EBIDTA margin outlook. Valuation: With its specialization strategy and focused approach, Bajaj auto aims to garner a higher share of the global motorcycle market together with industry leading profitability. Bajaj Auto would benefit on (a) upgrading in the domestic motorcycle market, driven by economic recovery, and (b) revival in exports which could offset the negative of absence in scooters. Further Bajaj Auto will have the first mover advantage in launch of quadricycle (expected in October 2014) in India. At CMP of Rs 2,351 the stock is trading at PE multiple of 16.5x FY16E EPS. We maintain BUY rating on the stock with target price of Rs. 2556 (18x FY16E EPS). Yogesh Hotwani Research Analyst Mobile: +91 77383 93373 Tel: +91 22 66188839 [email protected] Bajaj Finance Limited (Rs mn) Q2FY15E Q1FY15A Q2FY14A Net Interest Income 6,412 6,805 4,921 Pre Provisioning Profit 3,672 4,035 3,050 Net Profit 1,976 2,114 1,670 EPS (Rs) 39.4 42.2 33.6 % QoQ (6) (9) (7) (7) % YoY 30 20 18 17 Source: Company Filings, IndiaNivesh Research; Standalone We expect Asset Under Management (AUM) growth to remain strong at 36% yoy to Rs 269.8 bn largely led by strong growth in SME segment. Net interest income to grow by 30% yoy to Rs 6.4 bn. Net Interest margins to decline on qoq basis by 120 bps mainly due to lower disbursements in high yielding consumer segment due to seasonality. Operating profit to grow by 20% yoy to Rs 3.7 bn and Net profit to grow by 18% yoy to Rs 1.97 bn. We expect asset quality to remain stable across its business segments. Valuation: At CMP of Rs 2,687, Bajaj Finance is trading at P/ABV of 2.8x and 2.3x for FY15E and FY16E respectively. We have a hold rating on stock with target price of Rs 2,299. Key things to watch out for: 1) 2) IndiaNivesh Research Segmental break up of AUM and disbursement. Update on plan of launching housing finance company. NiveshDaily October 14, 2014 | 2 Results Preview (contd...) Amar Mourya Research Analyst NIIT Technologies (15-Oct-14) Tel: +91 22 66188836 [email protected] Rs in mn Net Sales ($ Mn) Net Sales EBITDA Net Profit EPS (Rs.) Q2FY15E Q1FY15A 95 5,733 757 417 7.0 60 96 5,776 775 432 7.2 60 Q2FY14A Q-o-Q % Ch. 93 5,873 886 624 10.4 60 ‐1.9% ‐0.7% ‐2.4% ‐3.5% ‐3.5% Y-o-Y % Ch. 1.3% ‐2.4% ‐14.6% ‐33.1% ‐33.1% bps EBITDA Margin (%) 13.2% PAT Margin (%) 7.3% Note: Consolidated Financials 13.4% 7.5% 15.1% 10.6% (22) (21) (189) (335) Source: Company Filings; IndiaNivesh Research Updates Sequentially, we expect $-revenue de-growth of 1.9% to Rs.95 mn, as descaling of U.S client revenue is likely to continue during the quarter. EBITDA margin is likely to contract by 22bps Q/Q, led by lower revenue base and lesser utilization. On account of lower EBITDA base, net profit is likely to de-grow 3.5% Q/Q to Rs.417 mn. Key things to watch out for: (1) fresh order intake, (2) revenue and margin outlook, and (3) commentary on uptick in U.S account which was ramped-down in last quarter. Valuation: At CMP of Rs. 401, the stock is trading at P/E multiple of 10.5x FY15E and 9.3x FY16 earnings estimate. We have HOLD rating with target price of Rs.414 on NIIT Tech. IndiaNivesh Research NiveshDaily October 14, 2014 | 3 Economy Update Consumer Price Index (CPI) inflation declines to 6.5% in September 2014; lowest since January 2012 Daljeet S. Kohli Head of Research Mobile: +91 77383 93371, 99205 94087 Tel: +91 22 66188826 [email protected] India’s CPI inflation rose 6.46% (combined) in September 2014 as compared to 7.80% in August 2014. It was below the street expectations of 7.2%. The corresponding inflation rates for rural and urban areas were 6.68% and 6.34%, respectively. The falling food prices pulled down the September 2014 CPI as food index increased 7.56% in September 2014 as compared to 9.22% in August 2014. Within the food inflation, inflation in vegetables was at 8.6% as compared to 15.2% in August 2014. However, fruits prices remain elevated as they increased 22.4% in September 2014 (24.3% in August 2014). Among other food items, milk & milk products continue to increase in double digits as it increased by 11.08% in September 2014. Encouragingly, core inflation, or non-food and non-fuel price inflation, slowed to 5.9% from 6.9% in August 2014, suggesting that demand-driven price pressures are weakening. Kaushal Patel Research Associate Mobile: +91 77383 93414 Tel: +91 22 66188834 [email protected] Our Take: The September CPI data surprised positively as it was the lowest since the new series of Consumer Price Index was released in January 2012 and below market expectations of 7.2%. While these numbers are positive and encouraging, it is important to see whether this trend continues. The drop in food inflation is largely because inflation of vegetables was nearly halved from 15.2% in August 2014 to 8.6% in September 2014. However, there are clearly seasonal factors which helped here as vegetable prices spiked in July and August due to uneven monsoon. The June to October period always sees fluctuations in prices of vegetable and fruits due to rain fall, and winter sees prices remaining subdued. Removing the supply side issues in agriculture and improving supply logistics will be of utmost importance for moderating food price pressures on sustainable basis. The working paper on food inflation by RBI also concludes that there is a need to raise agricultural productivity through enhanced investments and improved technology. However, if these issues are to be addressed by the government. Any agricultural sector reform will take at least two-three years to yield results on the ground. Overall, food Inflation uncertainty still exists in the economy. We expect the RBI’s January 2015 target of restricting CPI inflation below 8% to be comfortably achieved. However, we expect RBI to maintain status quo on rates in its next bi-monthly monetary policy which is scheduled for December 02, 2014 given the RBI’s goal of bringing retail inflation to 6.0% by January 2016. 12.00 Urban CPI Combined CPI Source: MOSPI, IndiaNivesh Research Jul-14 Sep-14 May-14 Jan-14 Mar-14 Sep-13 Nov-13 Jul-13 May-13 Jan-13 Mar-13 Jan-12 Sep-14 Jul-14 May-14 Jan-14 Mar-14 Nov-13 Jul-13 Sep-13 Mar-13 May-13 Jan-13 Nov-12 Jul-12 Sep-12 May-12 Jan-12 Mar-12 0.00 Nov-12 2.00 Jul-12 4.00 Sep-12 6.00 May-12 8.00 Mar-12 14.00 12.00 10.00 8.00 6.00 4.00 2.00 0.00 10.00 Rural CPI Source: MOSPI, IndiaNivesh Research 20.00 15.00 10.00 5.00 Food Fuel Housing Clothing Sep-14 Jul-14 May-14 Mar-14 Jan-14 Nov-13 Jul-13 Sep-13 Mar-13 May-13 Jan-13 Sep-12 Nov-12 Jul-12 May-12 Mar-12 Jan-12 0.00 Misc. Source: MOSPI, IndiaNivesh Research IndiaNivesh Research NiveshDaily October 14, 2014 | 4 Result Update October 14, 2014 Reliance Industries Ltd. (RIL) PAT above expectation, maintain buy with target price of Rs.1,274 Current Previous CMP : Rs.958 Rating : BUY Rating : BUY Target : Rs.1,274 Target : Rs.1,274 STOCK INFO BSE NSE Bloomberg Reuters Sector Face Value (Rs) Equity Capital (Rs Mn) Mkt Cap (Rs Mn) 52w H/L (Rs) Avg Daily Vol (BSE+NSE) 500325 RELIANCE RIL.IN RELI.BO Refineries 10 3234.2 3,095,490 1142/ 794 3,656,545 SHAREHOLDING PATTERN % (as on Sep. 2014) Institutions Others, Incl Public Promoters 30.78 23.96 45.26 RIL reported Q2FY15 PAT (Standalone) above street expectation on the back of higher than expected GRM and better petchem margin. Revenue decreased by 7% y-o-y (flat QoQ) to Rs. 964.86 bn (below consensus of Rs. 983 bn) due to lower refining and Oil & Gas revenue while Reported PAT stood at Rs. 57.4 bn (above consensus of Rs 55.81 bn). EBITDA margin above the consensus (stood at 8.5% vs. 8.1% of consensus) on the back of higher than expected GRM and better petchem margin. GRM for the quarter stood at $8.3/bbl vs. $8.7/bbl in Q1FY15 and $7.7/bbl in Q2FY14. RIL’s premium over Singapore GRM remains higher to $3.5/bbl vs. $2.5/bbl in Q2FY14 aided by wider crude differential and sourcing advantage. Revenue EBIDTA PAT Adjusted PAT Source: Company Filings; IndiaNivesh Research 3m -4 4 12m 12 30 Source: Capitaline, IndiaNivesh Research Q1 FY15 Q2 FY14 Q‐o‐Q % 964860 82350 57420 57420 963510 1037580 75300 78490 56490 54900 56490 54900 Y‐o‐Y % 0 0 -1 -3 -7 -7 -8 -11 consensus Q2FY15e 983,570 79,412 55,810 55,810 Variance(%) -1.9 3.7 2.9 2.9 Petchem EBIT margin stood at 9.64%, improved by 169 bps QoQ led by strong rebound in polymer, Fiber intermediates and aromatics margin. In E&P business, Average KG-D6 production stood at 12.5 MMSCMD of gas and 0.5 mmbbl of oil. Retail and US Shale gas business continues to make remarkable progress and registered 20% and 33.7% YoY growth in revenues, respectively. Outstanding debt as on 30th September 2014 was Rs 1420.8 bn ($ 23 billion) compared to Rs. 1387.61 (($ 22.6 billion) bn as on 31st March 2014. Cash and cash equivalents stood at Rs. 834.56 bn ($ 13.5 billion). Source: BSE STOCK PERFORMANCE (%) 1m RIL -5 SENSEX -3 Q2 FY15 Rs.mn RIL v/s SENSEX 170.00 Segment wise performance 160.00 150.00 140.00 130.00 120.00 110.00 Q2 FY15 Q1 FY15 Q2 FY14 Q‐o‐Q % Y‐o‐Y % FY14 FY13 Y‐o‐Y % 249.3 917.8 13.8 2.2 237.2 910.0 15.6 1.9 5.1 0.2 0.9 -5.8 -11.4 -5.7 14.5 -33.0 964.7 3619.7 60.7 15.5 881.1 3337.7 82.8 9.5 1183.1 1164.6 248.9 974.6 14.6 3.3 1241.4 1.6 -4.7 4661 4311 9.5 8.4 -26.7 62.5 8.1 24.0 37.9 3.3 0.7 18.9 37.7 4.9 0.5 27.5 0.4 -4.0 19.3 73.3 127.9 28.9 2.6 65.9 62.0 232.6 Segmental Revenue(Rs. bn) 100.00 90.00 80.00 RIL 10/9/2014 9/25/2014 9/11/2014 8/28/2014 8/14/2014 7/3/2014 7/31/2014 7/17/2014 6/5/2014 6/19/2014 5/8/2014 5/22/2014 4/24/2014 4/10/2014 3/27/2014 3/13/2014 2/27/2014 2/13/2014 1/2/2014 1/30/2014 1/16/2014 12/5/2013 12/19/2013 11/7/2013 11/21/2013 10/24/2013 10/10/2013 70.00 Sensex Source: Capitaline, IndiaNivesh Research Daljeet S. Kohli Head of Research Mobile: +91 77383 93371, 99205 94087 Tel: +91 22 66188826 [email protected] Petchem Refining Oil & Gas Others Total Segmental EBIT(R. bn) Petchem Refining Oil & Gas Others Total 25.0 31.7 3.6 0.4 60.8 Segmental EBIT Margin (%) Abhishek Jain Research Analyst Petchem Mobile: +91 77383 93433 Tel: +91 22 66188832 [email protected] Oil & Gas IndiaNivesh Research Refining Others -31.8 -6.7 26.9 57.1 86.1 132.2 16.3 4.2 6.3 8.4 238.8 Change in bps 9.6 4.1 24.1 29.9 7.9 4.1 31.3 26.9 10.1 3.3 24.3 12.7 169.0 -42.1 -1.9 87.0 -722.0 -25.9 292.1 1,713.7 17.5 3.4 -43.7 64.3 2.7 BPS 8.9 3.7 26.8 27.0 8.3 3.8 34.9 26.8 61.1 -17.9 -807.1 29.2 Source: Company Filings; IndiaNivesh Research; IndiaNivesh Securities Private Limited 601 & 602, Sukh Sagar, N. S. Patkar Marg, Girgaum Chowpatty, Mumbai 400 007. Tel: (022) 66188800 IndiaNivesh Research is also available on Bloomberg INNS, Thomson First Call, Reuters and Factiva INDNIV. Result Update (contd...) Refining GRM stood at USD 8.3/bbl in Q2FY15 vs. USD 7.7/bbl in Q2FY14 During Q2FY15, the refining division margin expand by 87 bps YoY on account of favorable currency movement and better GRM. GRM for the quarter stood at $8.3/bbl vs. $8.7/bbl in Q1FY15 and $7.7/bbl in Q2FY14. RIL’s premium over Singapore GRM remains higher to $3.5/bbl vs. $2.5/bbl in Q2FY14 aided by wider crude differential and sourcing advantage. Singapore GRM declined 19% QoQ (declined 8.3% YoY) from USD5.8/bbl to USD4.8/bbl, touching low of USD2.5/bbl in July-end, as auto-fuel cracks declined. Crude throughput stood at 17.3 MMT in Q2Y15, operating rate was at 112%. The company’s US$4bn pet coke gasification project remains on schedule for implementation by FY16 end. Operating Metrics(Refining (USD/bbl) RIL GRM Singapore GRM Premium Refinery Thr' put (mmt) Utilization (%) Q2 FY15 Q1 FY15 Q2 FY14 8.3 4.8 3.50 17.3 112 8.7 5.8 2.90 16.7 108 7.7 5.2 2.50 17.7 114 Q‐o‐Q % Y‐o‐Y % -4.6 7.8 -17.2 -7.7 20.7 40.0 3.6 -2.3 3.7 -1.8 FY14 FY13 Y‐o‐Y % 8.1 5.9 2.20 68 110 9.2 7.7 1.40 68.5 110 -12.0 -23.4 57.1 -0.73 0.00 Source: Company Filings; IndiaNivesh Research; Petrochemical segment: EBIT margin improved by 169 bps QoQ Petchem EBIT margin stood at 9.64% (v/s 7.9% in Q1FY15 and 10.1% in Q2FY14) improved by 169 bps QoQ led by strong rebound in polymer, Fiber intermediates and aromatics margin. Polyester production improved with the commissioning of the Silvassa plant Total production increased by 5.6% QoQ (flat YoY) to 5.7 MMT. Average natural gas production decreased to 12.5 MMSCMD in Q2 FY15 Average KG-D6 production stood at 12.5 MMSCMD of gas and 0.5 mmbbl of oil. RIL witnessed significant decline in gas production on yearly basis mainly attributed to geological complexity, natural decline in the fields and higher than envisaged water ingress. E&P (Gross Oil Production mmbbl PMT KG-D6 Gross gas production(mmscmd PMT KG-D6 To t a l Q2 FY15 Q1 FY15 Q2 FY14 Q‐o‐Q % Y‐o‐Y % FY14 FY13 Y‐o‐Y % 1.86 0.5 2.04 0.53 1.9 0.5 -8.8 -2.1 -5.7 0.0 7.4 2.03 8.2 2.91 -9.8 -30.2 6.3 12.5 18.8 7.1 13.0 20.1 7.4 13.9 21.3 -11.3 -14.6 -3.9 -6.5 -10.4 -11.8 7.1 13.7 20.9 9.0 26.4 36.9 -21 -48 -43 Shale gas business: revenue grew by 33.7% YoY IndiaNivesh Research Reliance’s shale business registered strong revenue growth of 33.7% Y-o-Y led by record production achieved at Pioneer and Chevron JVs. However, softening of benchmark gas prices impacted realization during the quarter. Reliance Industries Ltd|Result Update October 14, 2014 | 2 Result Update (contd...) Retail business on growth path The retail business performed well despite challenging macroeconomic environment. Total turnover increased by 20% YoY to Rs. 41.67 bn in 21FY15. EBIDTA contribution was Rs. 1.86 bn. Valuation We believe the company would be beneficiary of hike in natural gas price. RIL’s new refining/ petchem projects likely to add to earnings from end-FY16/FY17,Further, Shale Gas and Retail business are also showing remarkable growth and likely to be a key revenue and profitability drivers going ahead. At CMP Rs. 958 stock is trading at 10.5x FY16E EPS which is lower than its mean of 15x. We maintain buy rating on the stock with target price of Rs. 1,274. Quick Fundamentals (Rs. Mn) Reliance Net sales Income from operat Total Revenue Cost of Revenues Cost of materials consume Purchase of stock in trade change in inventory Staff cost other expenses EBIDTA Depreciation EBIT Interest Expense Other income Exceptioanl item PBT Provision for taxation PAT EPS (RS.) EBITDA % EBIT % PBT % PAT % Q2 FY15 964,860 964,860 882,510 788,510 Q1 FY15 Q2 FY14 963,510 1,037,580 963,510 1,037,580 888,210 959,090 809,660 883,650 17,360 -5,760 9,320 73,080 82,350 22,270 60,080 7,580 21,400 17,160 -21,200 9,290 73,300 75,300 20,240 55,060 3,240 20,460 1,160 -1,850 8,080 68,050 78,490 22,330 56,160 8,050 20,600 73,900 16,480 57,420 17.8 Margin % 8.5 6.2 7.7 6.0 72,280 15,790 56,490 17.5 Margin % 7.8 5.7 7.5 5.9 68,710 13,810 54,900 17.0 Margin % 7.6 5.4 6.6 5.3 Q‐o‐Q % 0.1 0.1 ‐0.6 ‐2.6 Y‐o‐Y % ‐7.0 ‐7.0 ‐8.0 ‐10.8 FY14 3,901,170 3,901,170 3,592,400 3,293,130 FY13 3,602,970 3,602,970 3,295,100 3,061,270 Y‐o‐Y % -7.6 -7.6 -8.3 -7 1.2 NA 0.3 ‐0.3 9.4 10.0 9.1 134.0 4.6 1,396.6 NA 15.3 7.4 4.9 ‐0.3 7.0 ‐5.8 3.9 5,240 4,120 33,700 256,210 308,770 87,890 220,880 32,060 89,360 5,020 -33,170 33,540 228,440 307,870 94,650 213,220 30,360 79,980 -4 -905 0 -11 0 8 -3 -5 -10 2.2 7.6 4.4 19.3 1.6 4.6 1.6 4.4 Basis Points (BPS) -72 25 -51 30 -16 88 -9 57 278,180 58,340 219,840 68.1 Margin % 7.9 5.7 7.1 5.6 262,840 52,810 210,030 64.2 Margin % 8.5 5.9 7.3 5.8 -6 -9 -4 -6 BPS 63 26 16 19 Source: Company Filings; IndiaNivesh Research; IndiaNivesh Research Reliance Industries Ltd|Result Update October 14, 2014 | 3 Result Update October 14, 2014 Liberty Shoes Ltd. Previous Disappointing performance on bottomline; downgrade to HOLD with revised target price of Rs 336 Rating : HOLD Rating : BUY Rs Mn Target : Rs.336 Target : Rs.400 Current CMP : Rs.315 STOCK INFO BSE 526596 NSE LIBERTSHOE Bloomberg LBS IN Reuters LIBS.BO Sector Footwear Face Value (Rs) 10 Equity Capital (Rs mn) 170 Mkt Cap (Rs mn) 5,368 52w H/L (Rs) (Adj.) 351/82 3m Avg Daily Volume (BSE + NSE) 418981 SHAREHOLDING PATTERN Net Sales EBIDTA Adj. PAT Adj. EPS Margin EBITDA (%) Adj. PAT (%) Source: BSE STOCK PERFORMANCE (%) 1m LIBERTY SHOES -2 SENSEX -3 3m 14 5 6.0 1.9 9.1 3.3 1,090 82 20 1.2 41.5 31.9 -6.9 5.1 -19.5 34.7 -19.5 34.7 QoQ (bps) YoY (bps) 7.5 -312 -153 1.8 -140 4 Liberty Shoes Ltd reported disappointing Q2FY15E results. The company has restated previous year figures to include Liberty Retail Revolutions Ltd, the recently merged retail subsidiary. Net sales were lower by 2.8% at Rs 1438 mn against our expectation of Rs 1479 mn. Domestic sales grew 35.3% yoy to reach Rs 1343 mn in Q2FY15 and exports grew 14.7% yoy to reach Rs 157.4 mn. The company has mentioned that it has completed major portion of the institutional order of Rs 480 mn which was missed last quarter. The balance order would be completed in Q3FY15E. During the quarter, the company added 16 new exclusive stores in Company Owned & Company Operated (COCO) & franchise format. Sales in own stores grew by ~20% yoy to reach Rs 200 mn in Q2FY15 against Rs 173 mn in Q2FY14. The company plans to add 80-100 more exclusive stores in franchise and COCO format in FY15E. As expected, higher proportion of low margin institutional orders have led to pressure on operating margins. EBITDA margin stood at 6% in Q2FY15 against 7.5% in Q2FY14, contraction of 153 bps (INSPL expectation: 7.5%). EBITDA of the company grew by 5.1% yoy to reach Rs 86 mn in Q2FY15 from Rs 82 mn in Q2FY14 (INSPL exp: Rs 111 mn, missed by 22.3%). Adj. PAT (adjusted for minor exceptional items) stood at Rs 27 mn in Q2FY15 against Rs 20 mn in Q2FY14, an increase of 34.7% yoy. However, this is far below our expectation of Rs 40 mn, disappointing by 33.2%. On half yearly basis, the net sales grew by 10.7% yoy to reach Rs 2454 mn in H1FY15 from Rs 2216 mn in H1FY14. Domestic sales grew 9.6% yoy to reach Rs 2291 mn in H1FY15 from Rs 2091 mn in H1FY14. Exports stood at Rs 272 mn in H1FY15 against Rs 207 mn in H1FY14, implying growth of 31.7% yoy. EBITDA of the company grew by a meagre 1.7% yoy to reach Rs 179 mn in H1FY15 from Rs 176 mn in H1FY14. EBITDA margin contracted 65 bps to reach 7.3% in H1FY15 from 7.9% in H1FY14. Adj. PAT stood at Rs 60 mn in H1FY15 against Rs 53 mn in H1FY14, growth of 13.6%. PAT growth was higher than EBITDA growth due to higher other income and decline in interest cost. 12m 279 29 Source: Capitaline, IndiaNivesh Research 1,016 93 33 1.9 % 64.9 0.0 0.0 35.1 1,438 86 27 1.6 INSPL Variance Estimate (%) 1479 -2.8 111 -22.3 40 -33.2 2.3 -33.2 Var (bps) 7.5 -151 2.7 -85 Source: Company, IndiaNivesh Research (as on 30th Jun. 2014) Promoters FIIs DIIs Public & Others Q2 FY15 Q1 FY15 Q2FY14 QoQ (%) YoY (%) LIBERTY SHOES v/s SENSEX 470 420 370 320 270 220 170 120 70 Oct/2014 Sep/2014 Jul/2014 Aug/2014 Jun/2014 Apr/2014 Liberty Shoes May/2014 Mar/2014 Jan/2014 Feb/2014 Dec/2013 Oct/2013 Nov/2013 20 Sensex Source: Capitaline, IndiaNivesh Research Daljeet S. Kohli Head of Research Mobile: +91 77383 93371, 99205 94087 Tel: +91 22 66188826 [email protected] Prerna Jhunjhunwala Research Analyst Mobile: +91 77388 92065 Tel: +91 22 66188848 [email protected] IndiaNivesh Research Estimates Revision Taking into consideration the H1FY15 performance, we are revising our estimates downward. Though topline disappointment has been lower, profitability has been grossly below our expectation. We have revised sales estimate downward by 6%/ 7% for FY15/FY16E. We do not expect the company to outperform FY14 EBITDA margin of 8.2% in FY15E. Hence we have revised our EBITDA margin expectations IndiaNivesh Securities Private Limited 601 & 602, Sukh Sagar, N. S. Patkar Marg, Girgaum Chowpatty, Mumbai 400 007. Tel: (022) 66188800 IndiaNivesh Research is also available on Bloomberg INNS, Thomson First Call, Reuters and Factiva INDNIV. Result Update (contd...) to 8.2% in FY15E. However, we expect the benefit of synergies of merger with retail subsidiary to kick in FY16E resulting in higher EBITDA margin of 8.8%, though lower than our earlier expectation of 9.1%. We have revised our EPS downward by 27% / 16% for FY15E / FY16E to stand at Rs 9.9 / 16.8 respectively. Particulars Rs Mn Net Sales EBIDTA Adj. PAT Adj. EPS Margin EBITDA (%) Adj. PAT (%) Now 5,808 473 168.1 9.9 FY15E Earlier 6,189 554 230 13.5 8.2 2.9 8.9 3.7 FY16E Now Earlier 7,410.3 8,009.0 653.6 730.4 286.1 340.2 16.8 20.0 QoQ (bps) YoY (bps) -80 8.8 9.1 -83 3.9 4.2 Var (%) -6 -15 -27 -27 Var (%) -7 -11 -16 -16 -30 -39 Source: IndiaNivesh Research Valuation and Outlook At CMP of Rs 315, the stock trades at PE of 31.9x and 18.8x its FY15E and FY16E earnings of Rs 9.9 and Rs 16.8 per share respectively. The company plans to expand its reach aggressively by increasing its store count to from 537 currently to 800 over the next three years. The synergy arising from merger of retail subsidiary are yet to show results. Also, the company is yet to come out with concrete plan on corporate restructuring. Both the events are key catalyst for the stock to perform. We retain our target multiple of 20x on the stock to arrive at target price of Rs 336 (earlier target price – Rs 400). We revise our rating to HOLD from BUY earlier. Financial Performance Rs in mn Q2 FY15 Q1 FY15 H1FY15 H1FY14 Net sales 1,438 1,016 1,090 41.5 31.9 2,454 2,216 10.7 Raw Materials Staff cost Other expenditure Operating Expenses 826 162 364 1,352 455 147 322 924 555 145 308 1,008 81.8 9.9 12.9 46.3 48.8 11.4 18.2 34.1 1,281 309 686 2,276 1,140 291 610 2,041 12.4 6.1 12.5 11.5 EBITDA EBITDA Margin (%) 86 6.0% 93 9.1% 82 7.5% ‐6.9 5.1 179 7.3% 176 7.9% 1.7 Other Operating Income Other Income Depreciation Profit bef. Int. & Tax 7 1 28 66 3 1 27 70 4 (0) 27 59 100.6 22.2 6.2 ‐6.2 63.0 ‐357.3 5.7 11.4 10 2 55 136 8 0 53 131 36.7 628.0 4.8 3.7 Interest & finance ch. Profit before tax 40 26 37 34 40 19 10.0 ‐23.9 ‐0.1 36.2 77 59 79 52 ‐2.7 13.5 Total tax expenses Adj. Net profit (1) 27 1 33 (1) 20 ‐286.9 ‐19.5 5.4 34.7 (0) 60 (0) 53 24.7 13.6 Exceptional Items Reported PAT (1) 25 0 33 0 20 ‐24.0 25.0 (1) 59 1 53 10.2 ‐4.0% 1.9% 1.6% 3.3% ‐5.2% 1.8% ‐0.8% 2.4% ‐0.7% 2.4% 1.6 1.9 1.2 3.5 3.1 Effective tax rate PAT Margins (%) Adj. EPS Q2FY14 QoQ (%) ‐19.5 YoY (%) 34.7 YoY(%) 13.6 Source: Company, IndiaNivesh Research IndiaNivesh Research Liberty Shoes Ltd.|Result Update October 14, 2014 | 2 Result Update (contd...) Financial Statements Balance sheet Income statement Y E March (Rs m) Net sales Growth % Expenditure Raw Material Advertisement and selling expenses Employee Others EBITDA Growth % EBITDA Margin % Other Income Depreciation and amortisation EBIT EBIT Margin % Interest Exceptional/Extraordinary item PBT PBT Margin % Tax Effective tax rate % PAT Before Minority Interest Minority Interest PAT After Minority Interest Adj. PAT Growth% FY 12 3564 15.0 3266 1716 443 437 670 298 29.4 8.4 13 97 214 6.0 138 -38 38 1.1 -4 ‐10 42 -2 44 82 ‐28.0 FY 13 3629 1.8 3345 1717 481 460 687 284 ‐4.9 7.8 20 104 199 5.5 143 -4 53 1.5 -1 ‐2 54 0 54 58 22.9 2.3 1.6 Y E March (Rs m) Net Profit Before Interest, Tax and Extraordinary Items Adjustment for: Depreciation Others Changes in working capital Tax expenses Cash flow from operations Capital expenditure Free Cash Flow Others Cash flow from investments Interest Loans availed or (repaid) FY 12 FY 13 165 179 302 370 543 97 -4 -28 -20 210 -98 111 3 ‐95 -127 -13 104 -18 45 -12 299 -95 205 -87 ‐182 -133 35 111 -12 -276 -11 114 -87 27 2 ‐84 -160 25 122 -10 76 -36 522 -177 345 2 ‐175 -170 136 131 -11 -568 -61 34 -185 ‐151 2 ‐183 -203 314 Refund of Share Application Money Dividend paid (incl tax) Cash flow from Financing Net change in cash Cash at the beginning of the year Cash at the end of the year Other Bank Balances Cash as per Balance Sheet -55 0 ‐195 -80 179 99 1 101 0 0 ‐98 19 101 120 4 124 0 0 ‐134 -105 124 19 4 23 0 -30 ‐64 283 23 306 4 310 0 -30 81 -68 310 243 4 247 Adj. PAT Margin % FY 14 FY 15E FY 16E 4835 5808 7410 33.2 20.1 27.6 4440 5334 6757 2534 3066 3890 643 772 986 591 697 874 672 799 1006 394 473 654 39.0 20.0 38.1 8.2 8.2 8.8 18 19 21 111 122 131 302 370 543 6.2 6.4 7.3 160 170 203 -2 0 0 140 200 341 2.9 3.4 4.6 8 32 55 6 16 16 132 168 286 0 0 0 132 168 286 134 168 286 145.2 27.3 70.2 2.8 2.9 Y E March (Rs m) Share Capital Reserves & Surplus Net Worth Total debt Net defered tax liability Total Liabilities Gross Fixed Assets Less Depreciation Capital Work in Progress Net Fixed Assets Goodwill on Consolidation Investments Current Assets Inventories Sundry Debtors Cash & Bank Balance Loans & advances Other Current assets Current Liabilities & provisions Net Current Assets Mis Exp not written off Total assets FY 12 FY 13 170 170 1147 1197 1318 1367 1047 1146 51 51 2416 2564 1767 1850 740 838 1 2 1028 1014 0 92 0 0 2293 2409 1028 1112 716 792 101 124 427 358 22 23 905 951 1388 1458 0 0 2416 2564 FY 14 170 1207 1378 1171 48 2597 1937 949 3 991 0 0 2696 1126 1175 23 333 40 1090 1606 0 2597 FY 15E 170 1345 1516 1307 44 2867 2114 1071 3 1046 0 0 3233 1278 1220 310 377 48 1411 1821 0 2867 FY 16E 170 1601 1772 1621 38 3430 2299 1202 3 1100 0 0 3935 1482 1704 247 445 57 1604 2331 0 3430 FY 12 FY 13 4.8 3.4 8.3 9.3 77.3 80.2 FY 14 7.9 14.3 80.9 FY 15E 9.9 17.0 89.0 FY 16E 16.8 24.5 104.0 3.9 Cash Flow Key ratios FY 14 FY 15E FY 16E Y E March Adj. EPS (Rs) Cash EPS (Rs) BVPS DPS (Rs) Adj. P/E (x) P/CEPS (x) P/BV (x) EV/EBITDA(x) M cap/sales (x) ROCE ROE Inventory (days) Debtors (days) Trade Payables (days) 0.0 0.0 1.5 1.5 1.5 65.4 38.2 4.1 18.9 1.3 92.7 34.0 3.9 20.1 1.3 40.1 22.1 3.9 14.8 1.0 31.9 18.5 3.5 12.0 0.8 18.8 12.9 3.0 9.3 0.6 9.0 3.3 8.2 4.0 11.9 9.6 13.8 11.6 17.5 17.4 104.5 107.6 68.4 75.8 69.1 69.4 84.5 74.2 54.5 75.5 75.2 56.1 68.0 72.0 55.9 Total Asset Turnover (x) Fixed Asset Turnover (x) 1.1 3.5 1.1 3.6 1.4 4.9 1.5 5.6 1.6 6.7 Debt/Equity (x) Debt/Ebitda (x) Interest Coverage (x) Dividend Yield % 0.8 3.5 1.6 0.0 0.8 4.0 1.4 0.0 0.8 3.0 1.9 0.5 0.9 2.8 2.2 0.5 0.9 2.5 2.7 0.5 Source: Company, IndiaNivesh Research IndiaNivesh Research Liberty Shoes Ltd.|Result Update October 14, 2014 | 3 Pharma Sector October 13, 2014 Q2FY15E Results Preview Aggregate y-y growth in earnings to slow down a bit on high base of past year; however outlook remains promising Target Price Reco (Rs) Ajanta Pharma 1,569 HOLD Alembic Pharma 412 HOLD Aurobindo Pharma 1,154 BUY Biocon 479 HOLD Cadila 1,553 BUY Cipla 632 HOLD Divis Lab 1,802 HOLD Dr Reddy 3,453 BUY Glenmark 775 HOLD Ipca Lab 868 BUY JB Chemicals 295 BUY Jubilant LifeSciences 154 HOLD Lupin 1,545 BUY Sharon Bio‐medicine 140 BUY Shilpa Medicare 542 HOLD Sun Pharma 754 HOLD Torrent 964 HOLD Company We expect 17 companies under INSPL pharma universe to deliver 20% y-y and 15% y-y growth in sales and adjusted PAT respectively for 2Q FY15. The major companies in the pack – Sun Pharma (SUNP IN) and Dr. Reddy’s Lab (DRRD IN), which contributes 32% and 12% to the aggregate adjusted PAT, are expected to show muted growth of 13% y-y and (11% y-y) for the quarter. This is due to lesser number of limited competition products and few launches in US market for SUNP as well as DRRD. However, the other major companies – Lupin and Aurobindo Pharma, which contributes 11% and 8% to the aggregate adjusted PAT are expected to show superior growth in earnings due to strong execution in US market. Lupin is expected to show robust growth in domestic formulation market as well. EBITDA margin is expected to remain stable at 25.9% for the quarter. The rupee has appreciated by ~3% y-y and remained at similar rate sequentially. This would have adverse impact on earnings compared to previous quarters, when companies had benefit of rupee depreciation. US generics is expected to grow by 27% y-y for the quarter: US generics remains the interesting opportunity for most of the Indian pharma players. In addition to plain vanilla generics and para IV filings, pharma companies have already started investing heavily in limited competition complex molecules. These opportunities have higher as well as sustained profitability unlike limited period profitability seen in FTF exclusivities. Though the opportunity remains promising, there could be quarterly volatility depending on product approvals from USFDA. As a result, we may see relatively lower y-y growth during the quarter. Source: IndiaNivesh Research High base of past year may result in downtrend in y-y growth in US generic segment Torrent Pharma is expected to show superior growth compared to peers 100,000 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 ‐ 70.0% 63.3% 56.7% 200.0 48.1% 50.0% 42.6% 40.0% 31.6% 27.0% 150.0 100.0 30.0% 20.0% 10.0% 58.6 Sep‐13 Dec‐13 Mar‐14 Revenue (in Rs Mn) Source: Company; IndiaNivesh Research Jun‐14 2Q FY15E 43.7 50.0 39.1 27.9 10.8 ‐ 0.0% Jun‐13 178.8 60.0% (50.0) Torrent Cadila Aurobindo Pharma Healthcare Pharma y‐o‐y Lupin (3.2) Dr Reddy's Sun Glenmark Lab Pharma Growth (y‐y, %) Note: Revenue growth in Rupee terms Source: Company; IndiaNivesh Research Daljeet S. Kohli Head of Research Mobile: +91 77383 93371, 99205 94087 Tel: +91 22 66188826 [email protected] Tushar Manudhane Research Analyst Aggregate domestic formulation is expected to grow by 17% y-y: After four quarters of slow growth till 4Q FY14, due to pricing cuts, domestic formulation segment is expected to show better performance in 2Q FY15. Domestic formulation segment has already showed improvement in 1Q FY15 and we expect this recovery to continue. Apart from new product launches and volume growth, pricing growth would also support the overall growth in domestic formulation going forward. The companies like Glenmark, Cipla and Sun Pharma would show superior growth compared to peers due to higher exposure to chronic portfolio. Mobile: +91 75066 45373 Tel: +91 22 66188835 [email protected] IndiaNivesh Research IndiaNivesh Securities Private Limited 601 & 602, Sukh Sagar, N. S. Patkar Marg, Girgaum Chowpatty, Mumbai 400 007. Tel: (022) 66188800 IndiaNivesh Research is also available on Bloomberg INNS, Thomson First Call, Reuters and Factiva INDNIV. Q2FY15E Results Preview (contd...) Domestic formulation growth on revival path for INSPL pharma universe 70,000 16.0% 60,000 50,000 40,000 11.0% 11.9% 16.9% 18.0% 12.7% 9.3% 30.0 14.0% 25.0 12.0% 20.0 10.0% 15.0 6.0% 20,000 4.0% 10,000 35.0 16.0% 8.0% 30,000 Addition of Elder products may result in abnormal y-y growth for Torrent Pharma 2.0% 31.8 18.8 18.0 18.0 18.0 15.0 15.0 14.0 12.0 11.5 10.0 5.0 0.0 0.0% Jun-13 Sep-13 Dec-13 Mar-14 Revenue (in Rs Mn) Jun-14 2Q FY15E y-o-y Growth (y-y, %) Source: Company; IndiaNivesh Research Source: Company; IndiaNivesh Research Though this quarter could be an aberration in terms of growth in earnings, we remain bullish on the sector as there are ample opportunities yet to be tapped by Indian pharma companies. The Indian pharma companies are building the foundation in terms of R&D and marketing to take the advantage of the opportunities in regulated as well as emerging markets. Our top picks are Aurobindo Pharma, Lupin, Cadila Healthcare, JB Chemicals, Sharon Bio-medicine and have BUY rating on the stocks. We continue to like Ajanta Pharma, Alembic Pharma, Divis Lab, Shilpa Medicare and Torrent Pharma. However, we have HOLD rating based on valuation. Valuations & Recommendation: Company Ajanta Pharma Alembic Pharma Aurobindo Pharma Biocon Cadila Cipla Divis Lab Dr Reddy Glenmark Ipca Lab JB Chemicals Jubilant LifeSciences Lupin Sharon Bio-medicine Shilpa Medicare Sun Pharma Torrent Sales (Rs mn) EBITDA Margin(%) FY15E FY16E FY15E FY16E 13,935 16,466 30.2 30.3 22,694 26,585 20.3 21.0 121,260 137,339 21.4 22.2 33,263 38,801 23.5 23.1 84,145 99,115 19.2 19.2 112,980 136,037 21.6 24.0 31,786 38,011 42.7 43.1 150,023 169,881 22.6 22.2 69,747 80,060 21.3 21.4 35,985 40,434 23.8 25.2 11,282 12,734 16.1 16.6 62,022 70,639 11.2 15.3 135,950 158,435 26.3 26.6 1,590 1,908 13.2 15.2 7,441 9,421 20.7 21.0 186,025 202,012 43.2 41.7 48,834 48,834 25.3 25.3 Adj. PAT (Rs mn) FY15E FY16E 2,772 3,262 3,124 3,834 15,470 18,650 4,608 5,320 10,287 10,287 14,240 20,305 9,951 11,962 22,035 24,401 8,965 10,460 5,501 6,847 1,559 1,784 1,127 2,638 24,357 28,859 113 173 994 1,306 62,357 65,078 7,826 7,826 EPS (Rs) FY15E FY16E 78.4 92.3 16.6 20.3 53.2 64.1 23.0 26.6 50.2 64.7 17.7 25.3 75.0 90.1 129.4 143.3 33.2 38.8 43.6 54.3 18.4 21.1 7.1 16.6 54.3 64.4 8.0 14.0 25.8 33.9 30.1 31.4 46.2 46.2 ROE (%) FY15E FY16E 32.9 28.9 28.7 25.1 30.5 28.0 13.8 14.3 24.5 25.6 16.9 21.0 28.7 27.2 21.0 20.2 26.7 25.0 32.4 32.1 18.6 20.8 4.7 13.9 27.1 25.2 5.4 7.6 20.2 21.2 44.3 43.2 31.1 31.1 P/E (x) Target Price Reco FY15E FY16E (Rs) 21.7 18.4 1,569 HOLD 23.4 19.0 412 HOLD 17.6 14.6 1,154 BUY 20.9 18.1 479 HOLD 26.3 20.4 1,553 BUY 33.4 23.4 632 HOLD 23.5 19.6 1,802 HOLD 23.2 20.9 3,453 BUY 21.4 18.3 775 HOLD 17.1 13.7 868 BUY 12.4 10.9 295 BUY 20.6 8.8 154 HOLD 24.4 20.6 1,545 BUY 8.9 5.1 140 BUY 21.0 15.9 542 HOLD 27.2 26.1 754 HOLD 18.3 18.3 964 HOLD Source: IndiaNivesh Research Ajanta Pharma Ltd: CMP= Rs 1700 Reco= HOLD, TP= Rs 1569 (Rs. In Mn.) SA Q2FY15E Q2FY14A Q1FY15A SALES EBITDA Adj Net Profit Forex (loss) Gain Reported Net profit Adj. EPS (Rs) 3,474 1,059 758 758 21.4 2,708 751 554 5 558 15.6 2,808 830 586 1 588 16.6 EBITDA Margins Net Margins 30.5 21.8 27.7 20.4 29.6 20.9 Y-o-Y Ch. Q-o-Q Ch. (%) (%) 28.3 23.7 41.1 27.6 36.9 29.2 35.8 29.0 36.9 29.2 bps bps 277 93 137 93 Source: Company; IndiaNivesh Research IndiaNivesh Research Pharma Sector October 13, 2014 | 2 Q2FY15E Results Preview (contd...) We expect Ajanta Pharma (AJP IN) to sustain the growth momentum with 28%y-y and 37% y-y growth in sales and adjusted PAT, respectively. Domestic formulation, Asia and Africa would drive growth in revenue as well as profitability for the quarter. EBITDA margin is expected to improve by 277bps on the back of improved operating leverage. Key factors to watch: Update of number of ANDAs filed and status of execution of new facility in Gujarat. Alembic Pharmaceuticals Ltd: CMP = Rs 387, Reco= HOLD, TP = Rs 412 Rs Mn Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch. (%) Q-o-Q Ch. (%) Sales 5,651 4,859 4,937 16.3 14.5 EBITDA 1,140 973 967 17.2 17.9 760 662 647 14.9 17.6 - - - - - Reported Net Profit 760 662 647 14.9 17.6 Adj EPS (Rs.) 4.03 3.51 3.43 14.9 17.6 bps Adj Net Profit Forex (loss) Gain EBITDA margins 20.2 20.0 19.6 15 bps 59 PAT Margins 13.5 13.6 13.1 (17) 36 Source: Company; IndiaNivesh Research Alembic Pharmaceuticals (ALPM IN) is expected to show sales of Rs5.6bn with 16.3% y-y growth for the quarter. The y-y growth would be mainly driven by higher exports, backed by new product approvals (Telmisartan) during the quarter. US sales are expected to grow at a strong rate of 42% y-y to US$26mn for the quarter. This would help ALPM to enhance EBITDA margin marginally to 20.2% and enable adjusted PAT to grow by 15% y-y to Rs760mn. Key factors to watch: Progress of execution of generic business. Pricing and volume growth in domestic formulation would also be the key factor to watch out. Aurobindo Pharma: CMP= Rs 938, Reco=BUY, TP= 1154 (Rs Mn) Sales Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch.(%) Q-o-Q Ch. (%) 28,980 18,975 28,946 52.7 0.1 6,582 4,129 42.4 (5.1) 34.3 (1.7) EBITDA 6,243 4,384 Net Profit 4,057 3,022 Forex (loss) Gain/other - (672) 26 (100.0) (100.0) 4,057 2,350 4,154 72.7 (2.3) 13.94 10.38 14.19 34.3 (1.7) bps bps EBITDA Margins (%) 21.5 23.1 22.7 (156) (120) Net Margins (%) 14.0 15.9 14.3 (193) (26) Net Profit Reported Adj EPS (Rs.) Source: Company; IndiaNivesh Research We expect Aurobindo Pharma (ARBP IN) to deliver robust performance during the quarter led by strong execution in US generics segment. We expect US generics sales to maintain strong momentum and grow by 48% y-y to US$175mn due to new product launches and increased market share in existing products. Overall sales are expected to grow by 53% y-y to Rs29bn and PAT to grow by 34% y-y to Rs4bn. However, the q-q EBITDA margin is expected to slip 120bps due to higher exclusivity related sales during 1Q FY15. Key factors to watch: progress on turnaround of acquired Actavis operations and performance in US market. IndiaNivesh Research Pharma Sector October 13, 2014 | 3 Q2FY15E Results Preview (contd...) Biocon Ltd: CMP = Rs 482 , Reco= HOLD, TP = Rs 479 BIOS IN (in Rs Mn) Out-licensing income Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch. (%) Q-o-Q Ch. (%) 34 190 7,304 6,996 Core sales 40 8,099 10.9 15.8 NET SALES 8,139 7,338 7,186 10.9 13.3 EBITDA 1,823 1,688 1,673 8.0 9.0 Adj Net Profit 1,175 1,022 1,030 14.9 14.0 Rep Net Profit 1,175 1,022 1,030 14.9 14.0 5.87 5.11 5.15 14.9 14.0 bps bps EPS (Rs.) Adj EBITDA Margins (%) 22.0 22.6 21.2 (63) 82 Net Margins (%) 14.0 13.5 12.0 48 200 Source: Company; IndiaNivesh Research Biocon is expected to show decent growth of 11% y-y in net sales and 15% y-y in adjusted PAT to Rs8bn and Rs1.2bn, respectively. The q-q performance is expected to be much better as 1Q FY15 was impacted by political issues in MENA region. Branded domestic formulation is expected to continue to do well in 2Q FY15, however, the growth rate would look high at 18% y-y due to low base of past year. Key factors to watch: Performance in domestic branded formulation segment, R&D spend, progress on various products in pipeline and performance in CRAMS business. Cadila Healthcare: CMP = Rs 1323, Reco = BUY, TP=Rs 1553 CDH IN (Rs Mn) Q2FY15E Q2FY14A 20,939 17,254 20,204 21.4 3.6 EBITDA 3,947 2,794 3,761 41.2 4.9 Adj Net Profit 2,551 1,897 2,414 34.5 5.7 - (63) (12) - - Rep Net Profit 2,551 1,834 2,402 39.1 6.2 EPS (Rs.) 12.46 9.26 11.79 34.5 5.7 bps bps EBITDA Margins (%) 18.8 16.2 18.6 265 23 Net Margins (%) 12.2 11.0 11.9 119 24 Sales Forex (loss) Gain Q1FY15A Y-o-Y Ch. (%) Q-o-Q Ch. Source: Company; IndiaNivesh Research We expect Cadila Healthcare to report revenue growth of 21.4% y-y and adjusted PAT growth of 35% y-y, led by strong execution in US generics. We expect US generics sales to grow by 62% y-y to US$125mn for the quarter. EBITDA margin is expected to remain stable at 18.8%, sequentially. We expect gradual pick up in revenues from domestic formulation segment. Key factors to watch: Progress on ANDA approvals and revival in growth of domestic formulation segment. Cipla Ltd: CMP= Rs 592, Reco= HOLD, TP = Rs 632 CIPLA IN (Rs Mn) Sales Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch. (%) Q-o-Q Ch. (%) 28,226 24,632 26,472 EBITDA 6,129 Adj Net Profit 3,615 5,642 3,205 - Forex (loss) Gain/Exceptional Rep Net Profit 14.6 6.6 5,418 8.6 13.1 2,696 12.8 34.1 400 400 - - 3,615 3,605 2,946 0.3 22.7 EPS (Rs.) 4.50 3.99 3.36 12.8 34.1 EBITDA Margins (%) 21.7 22.9 20.5 (119) 125 Net Margins (%) 12.8 13.0 10.2 (20) 262 bps bps Source: Company; IndiaNivesh Research IndiaNivesh Research Pharma Sector October 13, 2014 | 4 Q2FY15E Results Preview (contd...) We expect Cipla to show decent growth of 15% y-y and 13% y-y to Rs28bn and Rs3.6bn, respectively. The growth would be driven by domestic formulation and exports. EBITDA margin is expected to slip 119bps y-y due to higher expense related to building front end in US market. Key factors to watch: Progress on Inhaler launches in key European markets and building front end in US market. Divis Lab (SA): CMP= Rs 1765, Reco= HOLD, TP= Rs 1802 DIVI IN (SA Rs Mn) Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch. (%) Q-o-Q Ch. (%) 6,398 25.0 10.6 29.4 1,739 2,323 1,666 21.4 27.9 33.5 310 14 - (100.0) 2,224 2,049 1,679 8.5 32.4 16.75 13.10 27.9 33.5 bps bps Sales 7,074 5,659 EBITDA 3,006 2,477 Adj Net Profit 2,224 - Rep Net profit Adj EPS (Rs.) Forex (loss) gain 12.55 EBITDA Margins 42.5 43.8 36.3 (126) 619 Net Margins 31.4 30.7 26.0 70 540 Source: Company; IndiaNivesh Research Divis Laboratories is expected to show 25% y-y increase in sales to Rs7bn on account of increased contract orders from its customers. Relatively higher margin contracts would also result in improving EBITDA margins sequentially to 42.5% for the quarter and adjusted PAT to grow by 28% to Rs2.2bn. Key factors to watch: Revenue growth and improvement in EBITDA margins Dr Reddy’s Lab: CMP= Rs 3000, Reco= BUY, TP= Rs 3453 DRRD IN (Rs Mn) SALES Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch. (%) Q-o-Q Ch. (%) 15.2 9.9 6,289 4.4 11.6 5,503 (10.6) 5.7 38,667 33,575 35,175 Operating Profit (EBIT) 7,019 6,723 Adj Net Profit 5,818 6,508 Forex (loss) gain/ other - 394 21 NA - Rep Net Profit 5,818 6,903 5,526 (15.7) 5.3 EPS (Rs.) 34.25 38.32 32.40 (10.6) 5.7 bps bps EBIT Margins (%) 18.2 20.0 17.9 (187) 27 Net Margins (%) 15.0 19.4 15.6 (434) (60) Source: Company; IndiaNivesh Research Dr. Reddy’s Laboratories is expected to show 11% y-y decline in adjusted PAT to Rs5.8bn. Though sales are expected to grow by 15% y-y, EBITDA margin is expected to decline 187bps y-y due to higher limited competition products sales in 2Q FY14. US sales are expected to grow at moderate rate of 30% y-y to US$280mn due to lesser number of limited competition product launches during the quarter. Key factors to watch: performance in PSAI segment, domestic formulation segment and US market. R&D spend would also be the key factor to watch. IndiaNivesh Research Pharma Sector October 13, 2014 | 5 Q2FY15E Results Preview (contd...) Glenmark Pharmaceuticals Ltd: CMP= Rs 711, Reco= HOLD, TP=Rs 775 GNP IN (Rs Mn) Core sales Out-licensing income Total sales EBITDA Adj Net Profit Forex (loss) Rep Net Profit Adj EPS (Rs.) Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch. 15,869 14,512 14,570 9.3 118 299 15,869 14,630 14,869 8.5 3,476 3,039 3,124 14.4 1,934 1,425 1,550 35.7 1,934 1,543 1,849 25.3 7.1 5.3 5.7 35.7 bps 21.9 20.9 21.0 97 12.2 9.7 10.4 245 EBITDA Margins (%) Net Margins (%) Q-o-Q Ch. 8.9 6.7 11.3 24.8 NA 4.6 24.8 bps 89 176 Source: Company; IndiaNivesh Research Glenmark Pharmaceuticals is expected to show strong growth of 36% y-y in adjusted PAT partly on account of low base of past year and improvement in growth of domestic formulation segment. Though there were new product launches in US market, US sales is expected to remain stable y-y at US$90mn due to high base of past year. We expect domestic formulation sales to increase by 19% y-y to Rs5bn on the back of increased traction in existing products as well as new product launches. Overall sales are expected to grow by 9% y-y for the quarter. Key factors to watch: Revenue performance across the markets, EBITDA margins & any data point on R&D front. Ipca Labs (SA): CMP= Rs 744, Reco= BUY, TP= Rs 868 IPCA IN (Rs Mn) Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch. (%) Q-o-Q Ch. (%) Sales 9,409 8,343 9,282 12.8 1.4 EBITDA 2,299 2,345 2,309 (2.0) (0.4) Adj Net Profit 1,507 1,694 1,432 (11.0) 5.2 - (399) 23 - (100.0) Rep Net profit 1,507 1,295 1,455 16.4 3.6 Adj EPS (Rs) 11.94 13.42 11.35 (11.0) 5.2 bps bps Forex (loss) gain EBITDA Margins (%) 24.4 28.1 24.9 (367) (44) Net Margins (%) 16.0 20.3 15.4 (428) 59 Source: Company; IndiaNivesh Research We expect IPCA to show decent growth of 13% y-y in sales to Rs9.4bn, led by domestic branded and CIS branded segment. However, high base of past year is expected to result in adjusted PAT to decline by 11% to Rs1.5bn. Key factor to watch: Progress of clearance of USFDA issues at Ratlam facilty. JB Chemicals & Pharmaceuticals Ltd (SA): CMP= Rs 229, Reco=,BUY, TP= Rs 295 JBCL IN Rs Mn (SA) Sales Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch. (%) Q-o-Q Ch. (%) 2,821 2,475 EBITDA 524 Adj Net Profit 440 Forex (loss) gain/other - 2,567 14.0 9.9 446 420 17.6 24.9 407 276 8.2 59.2 (75) 42 - (100.0) Rep Net Profit 440 332 318 32.6 38.3 Adj EPS 5.2 4.8 3.8 8.2 38.3 EBITDA Margins (%) 18.6 18.0 16.4 56 224 Net Margins (%) 15.6 16.4 10.8 (83) 483 bps bps Source: Company; IndiaNivesh Research IndiaNivesh Research Pharma Sector October 13, 2014 | 6 Q2FY15E Results Preview (contd...) JB Chemicals is expected to show 14% y-y growth in sales, driven by healthy growth in exports as well as domestic formulation. Increased operating leverage is expected to result in EBITDA margin to improve from 16.4% to 18.6%. Adjusted PAT is expected to show relatively lower growth of 8.2% due to higher tax rate. Key factors to watch: Expansion in EBITDA margins & revenue growth in domestic market. Jubilant Life Sciences Ltd: CMP= Rs 146, Reco= HOLD, TP=Rs 154 JOL IN (Rs Mn) Sales EBITDA Adj Net Profit Q2FY15E Adj EPS Q1FY15A Y-o-Y Ch. Q-o-Q Ch. (%) 15,040 14,243 14,605 5.6 3.0 1,767 2,596 1,329 (31.9) 32.9 (15.1) 199 696 235 (71.4) - (1,502) (187) - - 199 (806) 48 NA 316.5 1.2 4.4 1.5 (71.4) (15.1) Forex (loss) gain Rep Net Profit Q2FY14A bps EBITDA Margins (%) Net Margins (%) bps 11.7 18.2 9.1 (648) 265 1.3 4.9 1.6 (356) (28) Source: Company; IndiaNivesh Research We expect Jubilant Life Sciences to show 71% y-y decline in adjusted PAT due to subdued performance in lifescience ingredients as well as pharmaceuticals business. The pharma segment was impacted in 1Q FY15 due to shut down at Montreal facility after USFDA warning letter. The site was closed for 10 weeks. We expect gradual improvement in sales from this site and as a result, the performance for the quarter is expected to be subdued. Sales are expected to grow by 5%y-y to Rs15bn and EBITDA is expected to decrease 276bps y-y to 15.5%. Key factors to watch: Pricing & volume growth, EBITDA margins, pricing scenario in chemical business and Symtet capacity utilization. Lupin Ltd: CMP= Rs 1328, Reco= BUY, TP= Rs 1545 LPC IN (Rs Mn) Sales Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch. (%) Q-o-Q Ch. (%) 32,462 26,315 32,840 EBITDA 9,286 49.0 (12.2) 5,478 6,232 4,062 10,579 Adj Net Profit 6,248 34.9 (12.3) - - - - - Rep Net Profit 5,478 4,062 6,248 34.9 (12.3) Adj EPS (Rs.) 12.25 9.09 13.98 34.9 (12.3) bps bps EBITDA Margins (%) 28.60 23.68 32.21 492 (361) Net Margins (%) 16.88 15.44 19.03 144 (215) Forex (loss) gain/exceptional 23.4 (1.2) Source: Company; IndiaNivesh Research We expect Lupin to deliver sustained growth in earnings, with 24% y-y growth in sales and 35% y-y growth in adjusted PAT to Rs32.5bn and Rs5.5bn, respectively. This would be driven by healthy growth in domestic formulation and strong growth in US market. We expect US sales to grow by 44% y-y to US$240mn led by increased traction in existing products. Key factors to watch: Progress on approvals of key products in US market and performance in domestic formulation segment. IndiaNivesh Research Pharma Sector October 13, 2014 | 7 Q2FY15E Results Preview (contd...) Sharon Biomedicine: CMP=Rs 71, Reco=BUY, TP= Rs 140 SBML IN (Rs Mn) Sales Q1FY15E Q1FY14A Q4FY14A Y-o-Y Ch.(%) Q-o-Q Ch. (%) 350 44 22 21 2.1 18.0 Adj Net Profit 25 Reported Net Profit 25 Adj EPS (Rs.) 2.4 315 34 16 15 1.5 12.0 10.8 12.7 6.8 5.2 6.3 372 EBITDA EBITDA Margins (%) 45 Net Margins (%) 6.5 30.8 0.5 53.0 14.7 63.3 22.8 63.3 14.7 bps 117 bps (72) 155 48 Note: Year ending June Source: Company; IndiaNivesh Research Sharon Biomedicine is expected to show 18% y-y growth in revenue and 63% y-y growth in adjusted PAT to Rs347mn and Rs25mn, respectively. Improved operating leverage and low base of past year would result in such high growth in adjusted PAT. Key factors to watch: Update of USFDA inspection, revenue growth and EBITDA margin. Shilpa Medicare Ltd : CMP=Rs 540, Reco=HOLD, TP= 542 SLPA IN (Rs Mn) Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch. (%) Q-o-Q Ch. (%) Sales 1,389 24.0 21.3 23.5 175 295 171 30.4 36.1 39.8 39 - - - 1,685 1,359 EBITDA 364 279 Adj PAT 239 - Forex (loss) gain/other Rep Net Profit 239 136 171 75.6 39.8 Adj EPS (Rs.) 6.19 4.55 4.43 36.1 bps 39.8 bps EBITDA Margins (%) 21.6 20.6 21.2 106 38 Net Margins (%) 14.2 12.9 12.3 126 187 Source: Company; IndiaNivesh Research We expect Shilpa Medicare to show strong growth of 24% y-y and 36% y-y in sales and adjusted PAT for the quarter on the back increased traction in oncology products and higher CRAMS business. EBITDA margin is expected to improve from 20.6% to 21.6% led by higher operating leverage. Key factors to watch: Growth in revenue and EBITDA, update on USFDA re-inspection at API unit in Raichur. Sun Pharmaceutical Industries Ltd: CMP=Rs 819, Reco = HOLD,TP= Rs754 SUNP IN (Rs Mn) Q2FY15E Q2FY14A Sales 47,562 41,921 39,269 13.5 21.1 EBITDA 20,556 15,382 18,284 17,239 12.4 19.2 13,623 13,905 12.9 10.6 - - - - - 15,382 13,623 13,905 12.9 10.6 7.7 4.9 7.39 56.9 3.7 bps bps Adj Net Profit Forex/exceptional item Rep Net Profit Adj EPS (Rs.) Q1FY15A Y-o-Y Ch. (%) Q-o-Q Ch. (%) EBITDA Margins (%) 43.2 43.6 43.9 (39) (68) Net Margins (%) 32.3 32.5 35.4 (16) (307) Source: Company; IndiaNivesh Research IndiaNivesh Research Pharma Sector October 13, 2014 | 8 Q2FY15E Results Preview (contd...) We expect Sun Pharmaceuticals to show 13.5% y-y and 13% y-y growth in sales and adjusted PAT, driven by healthy performance in domestic formulation. The high base effect in US market would result in relatively low growth in US markets. As a result, we expect US sales to grow at moderate rate of 14% y-y to US$ 478mn. Out of US$478mn, we expect Taro to contribute US$214mn for the quarter. We expect Taro sales to grow at modest rate of 4% y-y for the quarter due to high base of past year. We expect EBITDA margin to sustain at 43.2% due to superior product mix. Key factors to watch: Performance in key markets of India and US. Torrent Pharmaceutical Ltd: CMP=Rs 845, Reco=HOLD, TP = Rs 964 TRP IN (Rs Mn) Sales EBITDA Adj Net Profit Q2FY15E Q2FY14A Q1FY15A Y-o-Y Ch. Q-o-Q Ch. 12,927 9,360 10,920 38.1 18.4 2,800 1,796 1,430 1,030 3,230 95.8 (13.3) 2,560 74.3 (29.9) - - - Rep Net profit 1,871 1,130 2,560 65.5 (26.9) Adj EPS (Rs.) 10.61 6.09 12.23 74.3 (13.3) bps bps Forex (loss) gain - - EBITDA Margins (%) 21.7 15.3 29.6 638 (792) Net Margins (%) 13.9 11.0 23.4 288 (955) Source: Company; IndiaNivesh Research We expect Torrent Pharmaceuticals to deliver strong growth of 38% y-y and 74% yy in sales and adjusted PAT to Rs12.9bn and Rs1.9bn, respectively. This would be driven by superior growth in US market, addition of acquired business of Elder and healthy growth in its domestic formulation segment. We expect US sales to grow at significant rate of 184% y-y to US$47mn for the quarter. However, we expect sequential decline in EBITDA margin due to limited competition product in 1Q FY15. Key factors to watch: Progress on ANDA filing in US market and status of synergy post acquisition of Elder’s portfolio. IndiaNivesh Research Pharma Sector October 13, 2014 | 9 October 14, 2014 IndiaNivesh Universe | Valuation Table Company Nam e Auto Ashok Leyland** Bajaj Auto Eicher Motors** $$$ Exide Industries Hero MotoCorp Mahindra & Mahindra** Maruti Suzuki India Tata Motors Company** TVS Motor Company SKF India $$$ Sw araj Engines Rs. Mn Mcap Rs. CMP Rs. TP Reco % (-) Dow n/(+) Up 127,211 679,665 305,444 145,095 574,072 788,135 898,039 1,491,861 105,921 59,126 12,322 45 2,349 11,270 171 2,875 1,269 2,973 496 223 1,121 992 NA 2,556 NA 195 3,240 1,212 2,214 NA 146 808 1,184 NEUTRAL BUY NEUTRAL BUY BUY HOLD HOLD NOT RATED HOLD HOLD BUY NA 8.8 NA 14.2 12.7 -4.5 -25.5 NA -34.5 -27.9 19.3 Information Technology Infosys Tata Consultancy Services Wipro HCL Technologies### Tech Mahindra NIIT Technologies KPIT Cummins Mastek NIIT Ltd Thinksoft Services Ltd 2,263,955 5,320,982 1,442,538 1,231,376 557,549 24,492 31,170 5,839 8,630 NA 3,943 2,717 585 1,756 2,368 403 159 262 52 NA 3,952 2,666 611 1,697 2,151 414 190 550 55 494 HOLD HOLD HOLD HOLD HOLD HOLD BUY BUY HOLD HOLD 0.2 -1.9 4.5 -3.3 -9.2 2.8 19.3 110.0 5.3 NA Oil & Gas Cairn India Gail India Oil India Oil & Natural Gas Corporation Reliance Industries** 543,409 563,204 357,556 3,479,945 3,098,080 290 444 595 407 958 425 468 720 495 1,274 BUY BUY BUY BUY BUY 46.6 5.4 21.0 21.7 33.0 675 130 205 238 218 253 824 1,071 341 152 613 110 180 167 233 223 NA NA 366 216 SELL HOLD HOLD HOLD HOLD HOLD NOT RATED NOT RATED BUY HOLD -9.2 -15.1 -12.2 -29.7 6.8 -12.0 NA NA 7.5 42.2 Capital Goods Ingersoll Rand Greaves Cotton Crompton Greaves Voltas Bharat Heavy Elec (BHEL) Kirloskar Oil Engines Siemens ABB Alstom T&D BGR Energy Systems 21,323 31,637 128,452 78,585 534,066 36,652 293,318 226,964 87,197 10,958 (CMP as of previous day) Sales (Rs. Mn) FY14 FY15E FY16E 114,867 117,281 150,246 197,263 215,132 250,948 68,098 28,262 39,526 59,727 70,123 84,989 251,249 290,028 321,940 669,310 775,377 908,805 444,506 446,109 487,937 2,308,031 2,709,739 3,146,377 83,790 99,124 119,308 22,464 25,355 29,664 6,083 6,144 7,668 EBITDA (Rs.Mn) FY14 FY15E FY16E PAT (Rs. Mn) FY14 FY15E FY16E FY14 EPS (Rs.) FY15E FY16E P/E (x) FY15E FY16E 4,239 41,650 7,178 8,253 35,649 101,641 54,649 328,026 4,895 2,699 906 7,618 39,946 6,769 10,178 48,246 109,602 52,661 433,796 6,015 3,251 921 13,671 48,063 10,011 13,213 61,402 130,033 53,414 499,700 8,125 3,905 1,226 -1,641 33,803 3,939 4,872 21,027 46,669 28,529 119,604 1,863 1,667 670 457 35,353 4,976 6,346 25,599 48,420 28,444 188,922 3,179 2,252 702 5,610 41,098 7,576 8,362 36,434 59,464 30,374 218,397 4,627 2,711 915 -0.6 116.8 145.0 5.7 105.3 75.8 94.4 37.2 3.9 31.6 54.0 0.2 122.0 171.0 7.5 138.6 81.7 94.2 58.6 6.7 42.6 56.5 2.0 142.0 252.5 9.8 180.8 100.3 100.6 67.8 9.7 51.8 73.7 NA 19.3 65.9 22.8 20.7 15.5 31.6 8.5 33.3 26.3 17.6 22.7 16.5 44.6 17.4 15.9 12.6 29.6 7.3 23.0 21.7 13.5 539,008 604,062 963,693 1,127,343 490,894 556,458 379,099 433,537 217,827 248,231 23,142 25,724 30,195 33,468 10,533 12,559 10,099 12,125 2,349 2,827 133,604 251,528 95,078 86,660 42,076 3,631 4,204 726 598 399 146,449 293,779 106,080 98,358 45,959 3,587 4,938 959 793 552 176,100 340,321 123,185 109,193 53,147 4,090 5,690 1,184 974 576 105,999 191,639 77,967 63,690 30,288 2,305 2,490 518 178 300 117,556 223,323 81,481 72,698 31,372 2,292 2,959 738 -26 349 138,221 260,870 91,019 82,031 36,901 2,612 3,436 889 173 454 185.2 97.7 31.7 91.2 126.8 37.8 13.0 23.0 1.1 NA 205.5 114.1 33.1 102.8 138.6 38.2 14.9 33.1 4.2 22.3 237.3 129.0 36.9 116.0 161.6 43.5 17.3 39.9 4.9 36.3 19.2 23.8 17.7 17.1 17.1 10.5 10.7 7.9 12.4 NA 16.6 21.1 15.8 15.1 14.7 9.3 9.2 6.6 10.7 NA 187,612 186,668 214,665 616,435 541,034 724,424 97,157 127,422 132,396 1,744,771 1,940,109 2,075,083 4,344,600 4,371,150 4,512,389 137,504 80,111 37,028 491,947 357,610 130,548 73,712 54,833 689,961 413,339 147,238 74,443 65,638 785,040 478,879 124,318 47,862 29,420 265,065 224,930 109,247 45,173 37,277 319,860 251,856 125,002 49,411 44,469 375,794 264,314 65.0 37.7 48.9 31.0 76.6 57.2 35.6 62.0 37.4 80.7 65.4 39.0 74.0 42.9 90.5 5.1 12.5 9.6 10.9 11.9 4.4 11.4 8.0 9.5 10.6 455 1,877 6,820 2,693 67,764 3,067 4,383 4,699 3,380 3,992 459 2,197 9,779 3,624 41,631 2,949 6,766 5,731 3,882 4,520 610 2,659 11,125 4,378 44,331 3,274 10,003 7,526 4,834 4,650 670 1,234 2,443 2,454 35,029 1,785 1,940 1,769 1,170 932 681 1,455 4,658 3,111 35,448 1,935 3,348 2,750 1,315 1,607 775 1,788 5,218 3,458 37,998 2,153 5,612 4,068 2,453 1,654 21.2 5.1 3.9 7.4 13.9 12.3 5.5 8.4 3.5 12.9 21.6 6.0 5.1 5.0 14.5 14.2 10.3 12.4 5.1 18.5 24.5 7.3 6.3 6.5 15.5 15.4 16.3 17.9 9.6 17.7 31.3 21.6 40.3 47.5 15.1 17.8 80.1 86.7 66.8 8.2 27.6 17.7 32.5 36.6 14.1 16.5 50.5 59.8 35.5 8.6 499,365 818,094 434,269 329,170 188,314 23,050 26,940 9,096 9,510 1,944 5,787 17,359 134,806 52,437 403,660 22,870 113,526 76,316 35,638 33,008 6,259 17,648 147,648 56,566 412,187 23,272 110,800 80,496 37,291 38,246 6,961 19,131 154,587 61,835 422,196 24,725 123,683 91,240 42,616 39,968 IndiaNivesh Universe | Valuation Table (contd...) Company Nam e Cement ACC$$$ Ambuja Cements$$$ Ultratech Cement Prism Cement Mangalam Cement FMCG Bajaj Corp Godrej Consumer Products** Marico** Dabur** Tata Global Beverages** Pharma Ajanta Pharma Aurobindo Pharma Alembic Pharma Biocon Cadila Cipla Divis Lab Dr Reddy Glenmark Jubilant Life Science Lupin Sun Pharma Ipca Lab Torrent Pharma JB Chemical Shilpa Medicare Sharon Bio-Medicine Others BASF India Ltd.** && UPL Coromandel International Ltd. Sesa Sterlite ** Kajaria Ceramics Somany Ceramics Aditya Birla Nuvo Ltd.** Radico Khaitan Ltd.** Kaveri Seed Ltd** HSIL Ltd** Jindal steel and Pow er** Godaw ari pow er and Ispat ltd Liberty Shoes Ltd HIL Ltd Pennar Industries Ltd Rs. Mn Mcap Rs. CMP Rs. TP Reco % (-) Dow n/(+) Up 260,393 323,474 681,027 38,935 6,577 1,387 209 2,482 77 246 1,476 229 3,029 117 276 HOLD HOLD BUY BUY BUY 6.4 9.6 22.0 51.3 12.0 109,084 91,180 214,437 49,932 6,973 119,460 98,751 233,966 56,274 10,345 132,733 108,544 260,411 65,646 12,983 16,300 16,908 39,284 2,056 558 17,440 19,131 47,446 3,784 1,275 22,966 21,789 58,859 6,373 1,987 10,947 12,786 23,080 -862 296 40,614 321,038 190,818 370,417 97,398 275 943 296 211 158 215 UR UR UR 180 HOLD UR UR UR BUY -21.9 NA NA NA 14.3 6,707 76,024 46,865 70,734 77,376 7,593 87,082 56,568 81,383 82,157 8,522 100,998 64,871 93,916 89,344 1,860 11,784 7,591 11,690 7,521 2,369 13,605 8,686 13,600 8,099 NA 16,211 10,220 16,068 9,268 59,534 274,370 77,706 95,110 275,387 462,443 229,186 501,200 196,236 23,263 595,837 1,664,961 92,703 141,565 19,582 20,363 7,231 1,692 941 412 476 1,345 576 1,727 2,943 723 146 1,327 804 735 837 231 528 69 1,569 1,154 412 479 1,553 632 1,802 3,453 775 154 1,545 754 868 964 295 542 140 HOLD BUY HOLD HOLD BUY HOLD HOLD BUY HOLD HOLD BUY HOLD BUY HOLD BUY HOLD BUY -7.3 22.6 0.0 0.7 15.5 9.7 4.4 17.3 7.1 5.4 16.4 -6.2 18.1 15.2 27.8 2.6 104.4 12,083 80,366 18,632 28,773 70,600 101,004 25,253 132,170 60,052 58,034 112,866 160,804 32,288 40,363 10,006 5,482 13,248 13,935 121,260 22,694 33,263 84,145 111,016 31,786 150,023 69,747 62,022 135,950 186,025 35,985 48,834 11,282 7,441 15,897 16,466 137,339 26,585 38,801 99,115 126,616 38,011 169,881 80,060 70,639 158,435 202,012 40,434 48,834 12,734 9,421 19,077 3,690 21,396 3,615 7,249 12,207 21,572 10,152 25,465 11,004 11,165 30,859 71,969 8,141 10,545 1,546 1,222 1,575 4,208 24,481 4,614 7,810 16,154 22,763 13,570 33,898 14,876 10,034 33,204 78,457 8,552 12,338 1,817 1,539 1,987 55,332 143,540 83,594 740,724 49,738 12,158 209,942 11,880 56,708 26,580 145,515 4,894 5,377 4,739 6,330 1,278 335 293 250 658 313 1,614 89 823 402 159 149 316 635 53 NA 480 279 378 482 266 1,645 165 795 425 201 198 400 721 81 UR BUY HOLD BUY SELL HOLD BUY BUY HOLD BUY HOLD BUY BUY BUY BUY NA 43.3 -4.6 51.3 -26.8 -15.0 2.0 84.8 -3.4 5.6 26.4 32.5 26.8 13.5 54.0 42,347 107,709 71,269 661,524 18,387 12,629 258,934 14,122 10,111 18,582 200,040 15,409 4,835 8,657 11,133 51,646 121,670 111,207 798,283 20,972 15,853 277,997 15,878 12,126 22,029 259,617 17,103 6,189 10,984 16,366 54,907 138,703 125,040 897,619 27,748 20,483 310,730 17,859 14,608 26,642 315,044 18,976 8,009 13,840 20,784 3,642 20,484 9,982 203,918 2,818 868 46,232 1,935 2,213 2,651 55,287 2,119 394 406 898 3,772 23,250 9,675 278,210 3,271 1,013 53,413 2,273 2,970 3,229 74,281 2,854 554 1,074 1,637 Sales (Rs. Mn) FY14 FY15E FY16E EBITDA (Rs.Mn) FY14 FY15E FY16E FY14 EPS (Rs.) FY15E FY16E 10,989 14,122 25,327 525 450 14,444 17,381 31,961 1,990 979 58.2 8.3 84.1 -1.8 11.1 58.5 9.1 92.3 1.0 16.9 76.9 11.2 116.5 4.0 36.7 23.7 22.9 26.9 74.2 14.6 18.0 18.6 21.3 19.6 6.7 1,489 7,597 4,854 9,139 4,805 1,955 9,067 5,731 10,654 4,512 NA 11,102 6,813 12,668 5,273 10.1 22.3 7.5 5.2 7.8 13.3 26.5 8.8 6.1 7.3 NA 32.4 10.5 7.3 8.5 20.7 35.6 33.6 34.5 21.6 NA 29.1 28.2 28.9 18.5 4,989 25,212 5,593 8,970 19,983 28,079 16,400 37,794 17,166 11,701 39,121 81,584 9,722 13,622 2,113 1,978 2,575 2,339 11,729 2,355 4,138 8,036 13,884 7,733 21,515 5,423 1,090 18,364 31,415 4,785 6,639 615 757 703 2,772 15,470 3,124 4,608 10,287 13,022 9,951 22,035 8,965 1,127 24,357 62,357 5,501 7,826 1,559 994 1,054 3,262 18,650 3,834 5,320 10,287 16,853 11,962 24,401 10,460 2,638 28,859 65,078 6,847 7,826 1,784 1,306 1,471 66.4 40.2 12.5 20.8 39.3 17.3 58.3 126.0 20.0 6.9 40.8 15.2 37.9 39.2 7.3 19.6 4.7 78.4 53.2 16.6 23.0 50.2 16.2 75.0 129.4 33.2 7.1 54.3 30.1 43.3 49.1 18.4 25.8 10.0 92.3 64.1 20.3 26.6 64.7 21.0 90.1 143.3 38.8 16.6 64.4 31.4 52.6 46.2 21.1 33.9 13.9 21.6 17.7 24.8 20.7 26.8 35.6 23.0 22.7 21.8 20.6 24.4 26.7 17.0 18.9 12.5 20.5 6.9 18.3 14.7 20.3 17.9 20.8 27.4 19.2 20.5 18.6 8.8 20.6 25.6 14.0 18.1 10.9 15.6 4.9 4,513 27,784 10,879 309,468 4,414 1,320 62,431 2,469 3,677 4,107 84,648 3,152 730 1,748 2,182 1,279 9,498 3,565 62,985 1,242 289 11,429 712 2,090 340 19,104 578 132 71 260 1,601 13,285 5,310 68,836 1,405 451 14,047 875 2,895 1,082 22,736 907 230 563 713 1,899 16,723 6,052 87,104 2,127 646 17,770 947 3,637 1,283 23,871 1,146 340 1,019 1,063 23.6 21.6 15.4 21.5 16.7 8.3 91.1 3.7 30.3 5.1 20.5 17.7 7.9 14.3 2.0 37.0 31.0 18.8 23.5 17.7 11.6 108.1 7.0 39.6 16.0 23.0 27.7 13.5 75.4 5.4 43.0 40.2 21.4 30.0 26.8 16.6 153.4 7.5 48.4 26.0 25.5 35.0 20.0 136.5 8.1 34.6 10.8 15.6 10.6 37.2 27.0 14.9 12.8 20.8 25.2 6.9 5.4 23.4 8.4 9.7 29.7 8.3 13.7 8.3 24.6 18.8 10.5 12.0 17.0 15.5 6.2 4.3 15.8 4.7 6.5 FY16E PAT (Rs. Mn) FY14 FY15E P/E (x) FY15E FY16E IndiaNivesh Universe | Valuation Table (contd...) Company Nam e Telecom Bharti Airtel Idea Cellular Infra IRB Infra. Dev IL&FS Trans. Netw orks Reliance Infra Engineers India Larsen & Toubro Jaiprakash Associates Gujarat Pipavav Ports Real Estate Oberoi Realty Phoenix Mills Nesco Company Nam e Power Adani Pow er** CESC Ltd Coal India JSW Energy** NHPC NTPC Pow er Grid Corporation Reliance Pow er Torrent Pow er** Tata Pow er Company** Rs. Mn Rs. Rs. Mcap CMP TP Reco (-) Dow n/(+) Up % 1,565,182 561,961 392 156 NA NA SELL SELL NA NA 857,461 264,320 960,690 302,317 NA 341,618 277,778 81,430 318,003 95,230 355,776 109,318 27,727 19,678 77,158 41,757 153,376 79,349 1,342,039 73,582 79,236 232 169 583 236 1,446 30 164 226 246 NA 301 NA 94 151 HOLD BUY EXIT HOLD NOT RATED BUY HOLD -2.6 45.3 NA 27.8 NA 210.7 -7.9 37,319 65,870 190,337 18,465 851,284 198,344 5,830 47,924 72,571 247,011 19,405 642,293 261,957 7,308 57,491 74,321 NA 21,864 759,421 291,923 NA 17,652 19,031 31,720 3,889 110,951 65,313 2,880 21,758 20,237 46,061 4,424 75,061 87,015 3,864 25,529 22,945 NA 5,267 90,161 101,386 NA 70,193 52,680 17,549 214 364 1,245 308 329 1,680 BUY HOLD BUY 44.0 -9.5 34.9 7,842 14,485 1,413 11,498 14,782 2,140 13,435 17,168 2,698 4,205 6,792 1,039 6,285 7,421 1,548 Rs. Mn Mcap Rs. CMP Rs. TP Reco % (-) Dow n/(+) Up FY16E EBITDA (Rs.Mn) FY14 FY15E 124,498 89,654 2,152,617 121,692 210,896 1,156,426 705,480 200,847 65,836 230,299 43 718 341 74 19 140 135 72 139 85 50 NR 422 NA NA 190 164 118 NA 104 SELL NOT RATED HOLD NOT RATED NOT RATED BUY BUY BUY NOT RATED BUY 15.3 NA 23.8 NA NA 35.5 21.6 64.8 NA 22.1 Sales (Rs. Mn) FY14 FY15E Sales (Rs. Mn) FY14 FY15E 157,541 101,109 688,100 87,054 74,159 789,217 156,754 51,748 86,811 356,487 194,821 59,564 842,422 93,675 78,488 810,918 178,396 63,220 100,307 373,593 FY16E 206,000 63,367 891,311 95,036 81,428 889,763 210,265 89,011 102,305 392,487 EBITDA (Rs.Mn) FY14 FY15E 49,899 17,375 178,713 NA 44,460 198,795 133,129 19,167 13,046 77,118 66,541 15,535 208,109 33,143 51,106 228,669 152,433 21,394 18,993 84,519 FY16E FY14 EPS (Rs.) FY15E FY16E 29,683 24,488 NA 29,038 7.0 5.9 8.7 6.9 NA 8.2 7.0 7.0 6.2 6.1 4,591 4,630 19,137 4,827 49,020 -8,248 2,459 5,368 4,908 26,771 5,355 51,567 6,225 3,703 5,971 5,601 NA 6,350 61,620 13,992 NA 13.8 21.8 72.8 14.3 52.7 -3.7 4.4 16.2 18.5 71.2 15.9 53.9 -1.0 7.7 18.0 22.5 77.4 18.8 69.6 3.2 NA 8.1 11.5 7.6 12.3 18.6 9.4 20.4 6.8 10.1 NA 10.3 15.5 8.1 NA 7,295 9,322 2,039 3,111 1,285 816 3,966 2,153 1,159 4,787 3,221 1,473 9.5 8.9 58.0 12.1 20.2 82.2 14.6 23.6 104.5 10.5 12.4 8.9 9.0 9.9 7.6 FY16E PAT (Rs. Mn) FY14 FY15E FY16E FY14 EPS (Rs.) FY15E FY16E 5,594 7,241 208,341 11,841 25,220 105,659 66,617 19,735 1,759 18,516 -1.04 39.35 23.92 4.60 1.02 13.83 9.47 3.66 2.23 -1.61 -0.07 44.10 28.40 7.47 2.10 11.69 10.51 3.60 8.70 6.16 2.14 66.79 33.00 7.53 2.30 12.69 12.73 7.00 7.53 7.27 FY16E 72,169 16,233 240,101 31,718 52,458 207,209 180,051 39,784 19,274 87,191 PAT (Rs. Mn) FY14 FY15E -2,906 4,916 151,117 7,547 12,188 114,036 45,476 10,267 1,053 -2,600 -487 6,815 179,348 11,904 23,320 96,955 54,965 7,723 2,921 15,396 EV/EBITDA (x) FY15E FY16E P/BV (x) FY15E FY16E 1.9 1.5 4.5 1.6 0.7 1.3 1.8 1.0 1.0 1.5 1.7 1.3 3.9 1.5 0.7 1.2 1.6 0.9 1.1 1.4 IndiaNivesh Universe | Valuation Table (contd...) Company Nam e Banking & Financial Services State Bank of India Punjab National Bank Allahabad Bank Bank of Baroda Corporation Bank Federal Bank Canara Bank ICICI Bank HDFC Bank** Axis Bank DCB Bank Karur Vysya Bank Rs. Mn Mcap Rs. CMP Rs. TP Reco % (-) Dow n/(+) Up 1,855,570 333,213 55,468 371,594 54,560 116,040 173,272 1,710,388 2,116,878 912,951 21,103 55,841 2,485 920 102 865 326 136 376 1,478 877 387 84 521 3,003 860 87 1,058 NA 137 383 1,600 830 412 88 620 BUY HOLD SELL BUY NOT RATED HOLD HOLD HOLD HOLD HOLD HOLD BUY 20.8 -6.6 -14.6 22.3 NA 1.0 2.0 8.3 -5.3 6.5 4.6 19.0 492,822 161,460 53,113 119,654 37,837 22,286 89,444 164,756 191,096 119,516 3,684 12,837 565,451 180,094 60,883 135,576 43,107 24,292 105,599 183,854 223,081 132,326 4,726 14,497 633,554 201,079 67,548 154,389 50,840 27,693 124,515 207,915 270,240 145,617 5,959 17,362 321,092 113,845 40,204 93,532 30,394 14,804 67,962 165,946 149,386 114,561 1,880 8,378 373,776 126,411 42,062 102,214 34,848 16,307 76,545 184,169 176,227 126,220 2,500 9,054 423,230 141,865 47,937 118,014 43,195 19,064 86,643 213,622 216,178 139,779 3,366 11,203 108,912 33,426 11,720 45,411 5,617 8,389 24,382 98,105 87,435 62,177 1,514 4,296 9.5 -14.4 18.8 4.7 -6.5 18.5 18,989 22,153 19,821 116,830 2,295 4,038 22,004 28,032 23,929 137,304 2,658 5,202 25,688 34,554 28,626 157,365 3,088 6,581 18,470 13,490 13,929 5,060 1,466 1,278 21,253 16,854 16,360 5,574 1,712 1,949 24,856 20,562 19,421 6,703 1,995 2,750 13,172 7,190 5,948 1,395 1,287 370 LIC Housing Finance 161,290 320 350 BUY Bajaj Finance 134,747 2,687 2,299 HOLD L&T Finance Holding 112,860 66 78 BUY Max India+++ 83,758 314 329 HOLD CARE+++ 40,275 1,389 1,298 HOLD CFL 25,226 304 360 BUY Note: ** Bloomberg Est; +++ Manufacturing Format; $$$ Calendar Year; ### Y/E June, && EBIT Source: Company Filings; IndiaNivesh Research Net Interest Income (Rs. Mn) FY14 FY15E FY16E Pre-Tax Pre-Prov. Profit (Rs.Mn) FY14 FY15E FY16E PAT (Rs. Mn) FY14 FY15E FY16E FY14 EPS (Rs.) FY15E FY16E P/ABV (x) FY15E FY16E 132,987 40,315 11,077 50,972 2,729 9,652 26,394 107,636 104,083 66,947 1,899 4,759 155,704 45,235 13,827 61,329 7,322 11,339 29,322 121,254 128,683 73,274 2,060 5,870 146.0 92.0 21.5 105.4 33.5 9.8 52.9 85.0 36.3 132.0 6.0 40.1 178.0 111.0 20.3 118.4 16.3 11.3 57.2 93.0 43.1 142.0 7.6 39.5 209.0 125.0 25.4 142.4 43.7 13.3 63.6 105.0 53.4 156.0 8.2 48.7 1.9 1.2 0.9 1.1 0.8 1.6 0.8 2.2 4.0 0.4 1.7 1.6 1.7 1.1 0.8 1.0 0.8 1.4 0.7 2.0 3.4 0.4 1.4 1.5 14,126 8,791 7,072 1,551 1,452 847 16,524 10,640 9,019 1,777 1,680 1,299 26.1 143.0 3.5 5.2 44.4 4.5 28.0 177.0 4.1 5.8 50.1 10.3 32.7 214.0 5.2 6.7 57.9 14.1 1.9 2.8 1.7 2.7 7.1 2.1 1.7 2.3 1.5 2.5 6.1 1.9 Result Today Bajaj Auto Bajaj Finsv Bajaj Finance Bluedart Symphony 15-Oct-14 BajajHldng GRUH GSFC Mindtree NIIT Tech IndiaNivesh Securities Private Limited 601 & 602, Sukh Sagar, N. S. Patkar Marg, Girgaum Chowpatty, Mumbai 400 007. Tel: (022) 66188800 / Fax: (022) 66188899 e-mail: [email protected] | Website: www.indianivesh.in Disclaimer: This document has been prepared by IndiaNivesh Securities Private Limited (IndiaNivesh), for use by the recipient as information only and is not for circulation or public distribution. This document is not to be reproduced, copied, redistributed or published or made available to others, in whole or in part without prior permission from us. This document is not to be construed as an offer to sell or the solicitation of an offer to buy any security. Recipients of this document should be aware that past performance is not necessarily a guide for future performance and price and value of investments can go up or down. The suitability or otherwise of any investments will depend upon the recipients particular circumstances. The information contained in this document has been obtained from sources that are considered as reliable though its accuracy or completeness has not been verified by IndiaNivesh independently and cannot be guaranteed. Neither IndiaNivesh nor any of its affiliates, its directors or its employees accepts any responsibility or whatever nature for the information, statements and opinion given, made available or expressed herein or for any omission or for any liability arising from the use of this document. Opinions expressed are our current opinions as of the date appearing on this material only. IndiaNivesh directors and its clients may have holdings in the stocks mentioned in the report. To unsubscribe please send a mail to [email protected] Home IndiaNivesh Research NiveshDaily October 14, 2014 | 5 IndiaNivesh Research is also available on Bloomberg INNS, Thomson First Call, Reuters and Factiva INDNIV.
© Copyright 2024